ARS chief executive officer Sean Carrick recently appeared on RedChip’s Money Report, airing on the Bloomberg Network.
This author has yet to write their bio.Meanwhile lets just say that we are proud Nascent contributed a whooping 32 entries.
Entries by Nascent
SAN DIEGO, CA — May 9, 2019 – Nascent Biotech, Inc. (OTC: NBIO) founder Dr. Mark C. Glassy will present an abstract on a natural human lgG1 mAb, Pritumumab, which targets cell surface expressed vimentin and inhibits tumor growth, at the AAI convention this week in San Diego, California. Nascent CEO Sean Carrick stated, “We […]
Nascent Biotech founder Dr. Mark C. Glassy has co-authored a new paper appearing in Human Antibodies entitled, “Antibody drug conjugates: Progress, pitfalls, and promises.” Please click here to read a PDF version of the article.
Vero Beach, FL December 10, 2018 – Nascent Biotech, Inc. (OTC: NBIO) Received US Food and Drug Administration (FDA) Clearance to begin Phase 1 Clinical Trials effective December 7th, 2018. Nascent CEO Sean Carrick stated, “On Friday December 7, 2018, Nascent Biotech received a letter from the FDA moving the Company’s IND filing from Full […]
The British Journal of Cancer Research has just released a new paper co-authored by Nascent Biotech founder Dr. Mark C. Glassy entitled, “Prionogenicity of vimentin surmised from the sequelog of anti-idiotypic antibodies toward the paratope of malignant associatedautologous anti-vimentin antibody, CLN-IgG (Pritumumab)”. Click here to download the paper. Click here to download the supplementary information.
This October 22-24, 2018, in Riga, Latvia, Human Antibodies & Hybridomas Magazine will present its annual conference. Nascent Biotech will be one of the event’s primary sponsors, with Nascent Biotech founder Dr. Mark Glassy serving as the program chairman. Click this link to download a PDF detailing the conference details, and how to register.
The Economist has published a fascinating overview of cancer research’s progress, including immunotherapy: The greatest excitement is reserved for immunotherapy, a new approach that has emerged in the past few years. The human immune system is equipped with a set of brakes that cancer cells are able to activate; the first immunotherapy treatment in effect […]
Vero Beach FL, August 10, 2016 – Nascent Biotech, Inc., (“Nascent” or “the Company”) (BB: NBIO) is pleased to announce that through the non-dilutive funding recently received, it has paid nearly $1.7 million in payables and debt, plus created positive shareholders equity. “With this funding we are now able to advance our asset through accelerated […]
Development planned for multiple Epithelial Cancer Types, starting with brain cancer, in Mainland China. July 18, 2016 10:00 am EDT Dateline: TAIZHOU, Zhejiang Province, China & Vero Beach, FL, USA Public Company Information: OTC: NBIO Taizhou, Zhejiang Province, China & Vero Beach, FL USA.- Nascent Biotech, Inc. (OTC: NBIO), and Zhejiang Hisun Pharmaceutical Company Ltd., […]
Vero Beach, April 25th, 2016 – Nascent Biotech, Inc., (OTC.NBIO) is pleased to announce that it has been granted Orphan Drug Designation from the Office of Orphan Products Development of the FDA for its Pritumumab product for the treatment of Pancreatic cancer. According to Industry statistics, there are approximately 49,000 new cases of Pancreatic Cancer […]